GPRC5A and neoplasm: Future studies profiling Gprc5a−/−Kras mutant CSCs vs. parental cell xenotransplants may further aid in elucidating expression programs that embody an augmented malignant phenotype by CSCs, including expression cues associated with the host immune response and tumor microenvironment.